These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2174642)

  • 41. Editorial:
    Yadegar A; Nabavi-Rad A; Smith SM
    Front Cell Infect Microbiol; 2023; 13():1296784. PubMed ID: 37850053
    [No Abstract]   [Full Text] [Related]  

  • 42. [New macrolides].
    Lecomte F; Benhamou D
    Rev Med Interne; 1998 Apr; 19(4):255-61. PubMed ID: 9775151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mucus-Penetrating Nanoassembly as Potential Oral Phototherapeutic Formulation against Multi-Drug Resistant Helicobacter pylori Infection.
    Qiao Y; Han M; Fu H; Xu Y; Bai Y; Wang S; Yu J; Men C; Yin Y; Zhao X; Xi R; Meng M
    Small; 2024 May; 20(20):e2306909. PubMed ID: 38100246
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Solution NMR studies on Helicobacter pylori proteins for antibiotic target discovery.
    Lee KY; Lee BJ
    Expert Opin Drug Discov; 2016 Jul; 11(7):681-93. PubMed ID: 27216839
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori.
    Mégraud F
    Gastroenterology; 1998 Nov; 115(5):1278-82. PubMed ID: 9797385
    [No Abstract]   [Full Text] [Related]  

  • 46. 2-Substituted-5-nitroheterocycles: in vitro anti-Helicobacter pylori activity and structure-activity relationship study.
    Foroumadi A; Sorkhi M; Moshafi MH; Safavi M; Rineh A; Siavoshi F; Shafiee A; Emami S
    Med Chem; 2009 Nov; 5(6):529-34. PubMed ID: 19673692
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of Helicobacter pylori infection. Development of resistance to antibiotics used must be avoided.
    Rao GG; O'Donohue J; Mahankali Rao CS; Fidler H
    BMJ; 2000 Jun; 320(7248):1540. PubMed ID: 10877582
    [No Abstract]   [Full Text] [Related]  

  • 48. Helicobacter pylori-targeting multiligand photosensitizer for effective antibacterial endoscopic photodynamic therapy.
    Im BN; Shin H; Lim B; Lee J; Kim KS; Park JM; Na K
    Biomaterials; 2021 Apr; 271():120745. PubMed ID: 33740616
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antimicrobial activity of natural products against Helicobacter pylori: a review.
    Bonifácio BV; dos Santos Ramos MA; da Silva PB; Bauab TM
    Ann Clin Microbiol Antimicrob; 2014 Nov; 13():54. PubMed ID: 25406585
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CuO nanoparticles for green synthesis of significant anti-Helicobacter pylori compounds with in silico studies.
    Shehab WS; Elsayed DA; Abdel Hamid AM; Assy MG; Mouneir SM; Hamed EO; Mousa SM; El-Bassyouni GT
    Sci Rep; 2024 Jan; 14(1):1608. PubMed ID: 38238369
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intervenolin, a new antitumor compound with anti-Helicobacter pylori activity, from Nocardia sp. ML96-86F2.
    Kawada M; Inoue H; Ohba S; Hatano M; Amemiya M; Hayashi C; Usami I; Abe H; Watanabe T; Kinoshita N; Igarashi M; Masuda T; Ikeda D; Nomoto A
    J Antibiot (Tokyo); 2013 Sep; 66(9):543-8. PubMed ID: 23632919
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antiradical activity and in vitro inhibition of Helicobacter pylori by Italian red wines.
    Biagi M; Miraldi E; Figura N; Giachetti D
    Nat Prod Commun; 2009 Feb; 4(2):255-60. PubMed ID: 19370934
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biomaterials for
    Lai Y; Wei W; Du Y; Gao J; Li Z
    Gut Microbes; 2022; 14(1):2120747. PubMed ID: 36070564
    [No Abstract]   [Full Text] [Related]  

  • 54. Acrylate-tethering drug carrier: covalently linking carrier to biological surface and application in the treatment of Helicobacter pylori infection.
    Tachaprutinun A; Pan-In P; Samutprasert P; Banlunara W; Chaichanawongsaroj N; Wanichwecharungruang S
    Biomacromolecules; 2014 Nov; 15(11):4239-48. PubMed ID: 25300443
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Overcoming the challenges to developing new antibiotics.
    Shlaes DM; Spellberg B
    Curr Opin Pharmacol; 2012 Oct; 12(5):522-6. PubMed ID: 22832234
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dealing with uncertainty in the treatment of
    Calvet X
    Ther Adv Chronic Dis; 2018 Apr; 9(4):93-102. PubMed ID: 29623181
    [No Abstract]   [Full Text] [Related]  

  • 57. Coptisine-induced inhibition of Helicobacter pylori: elucidation of specific mechanisms by probing urease active site and its maturation process.
    Li C; Huang P; Wong K; Xu Y; Tan L; Chen H; Lu Q; Luo C; Tam C; Zhu L; Su Z; Xie J
    J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1362-1375. PubMed ID: 30191728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Response to metronidazole and oxidative stress is mediated through homeostatic regulator HsrA (HP1043) in Helicobacter pylori.
    Olekhnovich IN; Vitko S; Valliere M; Hoffman PS
    J Bacteriol; 2014 Feb; 196(4):729-39. PubMed ID: 24296668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Association of a probiotic to a Helicobacter pylori eradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study.
    Navarro-Rodriguez T; Silva FM; Barbuti RC; Mattar R; Moraes-Filho JP; de Oliveira MN; Bogsan CS; Chinzon D; Eisig JN
    BMC Gastroenterol; 2013 Mar; 13():56. PubMed ID: 23530767
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication.
    Eisig JN; Silva FM; Barbuti RC; Rodriguez TN; Malfertheiner P; Moraes Filho JP; Zaterka S
    BMC Gastroenterol; 2009 May; 9():38. PubMed ID: 19470177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.